The effect of botulinum toxin A on patients with persistent idiopathic dentoalveolar pain-A systematic review.
botulinum toxin A
neuropathic pain
orofacial pain
Journal
Journal of oral rehabilitation
ISSN: 1365-2842
Titre abrégé: J Oral Rehabil
Pays: England
ID NLM: 0433604
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
11
02
2020
revised:
01
06
2020
accepted:
30
06
2020
pubmed:
9
7
2020
medline:
26
8
2020
entrez:
9
7
2020
Statut:
ppublish
Résumé
It has been suggested that botulinum toxin A (BONT-A) is a safe and effective treatment in relieving pain in patients with persistent idiopathic dentoalveolar pain (PIDP). This study aimed to systematically evaluate all the available studies investigating the pain-relieving effects of BONT-A in patients with PIDP. A systematic search with specific search terms was made in PubMed, Web of Science and Scopus. Two authors screened titles and abstracts and selected eligible studies for inclusion in the systematic review. The quality of the studies was evaluated by the 12 items Quality Assessment Tool for Observational studies (Pre-Post) Studies with No Control Group, and the level of evidence was assessed according to GRADE. Three observational studies of 3695 identified were included (445 overlapping studies; 3247 excluded studies). All studies were uncontrolled observational studies investigating the pain-relieving effect of BONT-A in patients with PIDP. The included studies had a fair quality (moderate risk of bias) and insufficient level of evidence. The pain reducing effect by BONT-A injections was in average 50% or more in two studies, in one study 3 out of 4 patients became almost pain free. This systematic review shows that presently the level of scientific evidence is insufficient to evaluate the pain-relieving effect of BONT-A injections in patients with PIDP. There are indications that BONT-A injections could be a possible management option for patients with PIDP that seems to be safe and with few adverse events. There is a need for well-designed placebo-controlled, double-blind RCTs.
Sections du résumé
BACKGROUND
BACKGROUND
It has been suggested that botulinum toxin A (BONT-A) is a safe and effective treatment in relieving pain in patients with persistent idiopathic dentoalveolar pain (PIDP).
OBJECTIVES
OBJECTIVE
This study aimed to systematically evaluate all the available studies investigating the pain-relieving effects of BONT-A in patients with PIDP.
METHODS
METHODS
A systematic search with specific search terms was made in PubMed, Web of Science and Scopus. Two authors screened titles and abstracts and selected eligible studies for inclusion in the systematic review. The quality of the studies was evaluated by the 12 items Quality Assessment Tool for Observational studies (Pre-Post) Studies with No Control Group, and the level of evidence was assessed according to GRADE.
RESULTS
RESULTS
Three observational studies of 3695 identified were included (445 overlapping studies; 3247 excluded studies). All studies were uncontrolled observational studies investigating the pain-relieving effect of BONT-A in patients with PIDP. The included studies had a fair quality (moderate risk of bias) and insufficient level of evidence. The pain reducing effect by BONT-A injections was in average 50% or more in two studies, in one study 3 out of 4 patients became almost pain free.
CONCLUSIONS
CONCLUSIONS
This systematic review shows that presently the level of scientific evidence is insufficient to evaluate the pain-relieving effect of BONT-A injections in patients with PIDP. There are indications that BONT-A injections could be a possible management option for patients with PIDP that seems to be safe and with few adverse events. There is a need for well-designed placebo-controlled, double-blind RCTs.
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1184-1191Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia. 2020;40(2):129-221.
Nixdorf DR, Drangsholt MT, Ettlin DA, et al. Classifying orofacial pains: a new proposal of taxonomy based on ontology. J Oral Rehabil. 2012;39(3):161-169.
Nixdorf DR, Moana-Filho EJ, Law AS, McGuire LA, Hodges JS, John MT. Frequency of persistent tooth pain after root canal therapy: a systematic review and meta-analysis. J Endod. 2010;36(2):224-230.
Malacarne A, Spierings ELH, Lu C, Maloney GE. Persistent dentoalveolar pain disorder: a comprehensive review. J Endod. 2018;44(2):206-211.
Woda A, Pionchon P. A unified concept of idiopathic orofacial pain: clinical features. J Orofac Pain. 1999;13(3):172-184; discussion 85-95.
Pigg M, List T, Petersson K, Lindh C, Petersson A. Diagnostic yield of conventional radiographic and cone-beam computed tomographic images in patients with atypical odontalgia. Int Endod J. 2011;44(12):1092-101.
List T, Leijon G, Helkimo M, Oster A, Dworkin SF, Svensson P. Clinical findings and psychosocial factors in patients with atypical odontalgia: a case-control study. J Orofac Pain. 2007;21(2):89-98.
List T, Leijon G, Svensson P. Somatosensory abnormalities in atypical odontalgia: a case-control study. Pain. 2008;139(2):333-341.
Pigg M, List T, Abul-Kasim K, Maly P, Petersson A. A comparative analysis of magnetic resonance imaging and radiographic examinations of patients with atypical odontalgia. J Oral Fac Pain Headache. 2014;28(3):233-242.
Baad-Hansen L, List T, Kaube H, Jensen TS, Svensson P. Blink reflexes in patients with atypical odontalgia and matched healthy controls. Exp Brain Res. 2006;172(4):498-506.
Takenoshita M, Sato T, Kato Y, et al. Psychiatric diagnoses in patients with burning mouth syndrome and atypical odontalgia referred from psychiatric to dental facilities. Neuropsychiatr Dis Treat. 2010;6:699-705.
Ciaramella A, Paroli M, Lonia L, Bosco M, Poli P. Biopsychosocial aspects of atypical odontalgia. ISRN Neurosci. 2013;2013:413515.
Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
Clark GT. Persistent orodental pain, atypical odontalgia, and phantom tooth pain: when are they neuropathic disorders? J Calif Dent Assoc. 2006;34(8):599-609.
Brooke RI, Schnurr RF. Diagnosing and treating atypical odontalgia. J Mass Dent Soc. 1995;44(1):30-32.
Melis M, Secci S. Diagnosis and treatment of atypical odontalgia: a review of the literature and two case reports. J Contemp Dent Pract. 2007;8(3):81-89.
Schnurr RF, Brooke RI. Atypical odontalgia. Update and comment on long-term follow-up. Oral Surg Oral Med Oral Pathol. 1992;73(4):445-448.
Padilla M, Clark GT, Merrill RL. Topical medications for orofacial neuropathic pain: a review. J Am Dent Assoc. 2000;131(2):184-195.
Cuadrado ML, Garcia-Moreno H, Arias JA, Pareja JA. Botulinum Neurotoxin Type-A for the Treatment of Atypical Odontalgia. Pain Med. 2016;17(9):1717-1721.
Garcia-Saez R, Gutierrez-Viedma A, Gonzalez-Garcia N, Gomez-Mayordomo V, Porta-Etessam J, Cuadrado ML. Onabotulinum toxin A injections for atypical odontalgia: an open-label study on nine patients. J Pain Res. 2018;11:1583-1588.
Moreno-Hay I, Mishra P, Okeson JP. Intraoral Administration of Botulinum Toxin for Continuous Dentoalveolar Neuropathic Pain: A Case Series. J Oral Fac Pain Headache. 2019;33(2):160-164.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2009;3(3):e123-e130.
Higgins JPT, G. S. Cochrane handbook for systematic reviews of interventions version 5.1.0: Cochrane Collaboration 2011. Available from: http://handbook-5-1.cochrane.org/
NIH. Quality Assessment Tool for Before-After (Pre-Post) Studies With No Control Group 2014 [Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed). 2008;336(7650):924-926.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
Wieckiewicz M, Grychowska N, Zietek M, Wieckiewicz G, Smardz J. Evidence to use botulinum toxin injections in tension-type headache. management: a systematic review. Toxins (Basel). 2017;9(11):370.
Bruloy E, Sinna R, Grolleau JL, Bout-Roumazeilles A, Berard E, Chaput B. Botulinum toxin versus placebo: a meta-analysis of prophylactic treatment for migraine. Plast Reconstr Surg. 2019;143(1):239-250.
Yuan RY, Sheu JJ, Yu JM, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473-1478.
Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857-864.
Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274-283.
Attal N, de Andrade DC, Adam F, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15(6):555-565.
Beaudoin M, Best KL, Routhier F. Influence of peer-based rehabilitation interventions for improving mobility and participation among adults with mobility disabilities: a systematic review. Disabil Rehabil. 2020;42(13):1785-1796.
Borges Migliavaca C, Stein C, Colpani V, et al. Isosorbide and nifedipine for Chagas' megaesophagus: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2018;12(9):e0006836.
Sim WS. Application of botulinum toxin in pain management. Korean J Pain. 2011;24(1):1-6.
Moreau N, Dieb W, Descroix V, Svensson P, Ernberg M, Boucher Y. Topical review: potential use of botulinum toxin in the management of painful posttraumatic trigeminal neuropathy. J Oral Fac Pain Headache. 2017;31(1):7-18.
Wittekindt C, Liu WC, Preuss SF, Guntinas-Lichius O. Botulinum toxin A for neuropathic pain after neck dissection: a dose-finding study. Laryngoscope. 2006;116(7):1168-1171.
Han ZA, Song DH, Oh HM, Chung ME. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann Neurol. 2016;79(4):569-578.
Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology. 2001;56(10):1290-1293.
Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013;14:92.
Wei J, Zhu X, Yang G, et al. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials. Brain Behav. 2019;9(10):e01409.
List T, Leijon G, Helkimo M, Oster A, Svensson P. Effect of local anesthesia on atypical odontalgia-a randomized controlled trial. Pain. 2006;122(3):306-314.
Wang Y, Gao B. A dose-response relationship research on botulinum toxin type A local intramuscular injections of lower extremity spasticity in children with cerebral palsy. Child Nerv Syst. 2008;24(5):545-547.
Zhang H, Lian Y, Ma Y, Chen Y, He C, Xie N et al Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014;15:65.
Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology. 2013;306:124-146.